Cart
sales@molnova.com
Sunifiram
CAS No. 314728-85-3
Sunifiram( DM-235 )
Catalog No. M20948 CAS No. 314728-85-3
Sunifiram is a potent nootropic agent.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 1 mL x 10 mM in DMSO | 28 | In Stock |
|
| 10MG | 34 | In Stock |
|
| 25MG | 57 | In Stock |
|
| 50MG | 84 | In Stock |
|
| 100MG | 124 | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | 313 | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameSunifiram
-
NoteResearch use only, not for human use.
-
Brief DescriptionSunifiram is a potent nootropic agent.
-
DescriptionSunifiram is a potent nootropic agent.
-
In Vitro——
-
In Vivo——
-
SynonymsDM-235
-
PathwayMembrane Transporter/Ion Channel
-
TargetiGluR
-
RecptoriGluR
-
Research AreaNeurological Disease
-
IndicationAlzheimer's disease
Chemical Information
-
CAS Number314728-85-3
-
Formula Weight246.3
-
Molecular FormulaC14H18N2O2
-
Purity>98% (HPLC)
-
SolubilityDMSO:2.6 mg/mL (10.56 mM); H2O:50 mg/mL (203.00 mM)
-
SMILESCCC(=O)N1CCN(C(=O)c2ccccc2)CC1
-
Chemical Name1-(4-Benzoylpiperazin-1-yl)propan-1-one
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1.Romanelli M N Galeotti N Ghelardini C et al. Pharmacological Characterization of DM232 (Unifiram) and DM235 (Sunifiram) New Potent Cognition Enhancers[J]. CNS drug reviews 2006 12(1):39-52.
molnova catalog
related products
-
Dynorphin A 1-10
Dynorphin A (1-10), an endogenous opioid neuropeptide, binds to extracellular loop 2 of the κ-opioid receptor. Dynorphin A (1-10) also blocks NMDA-activated current with an IC50 of 42.0 μM.
-
TAK-137
TAK-137 is an AMPA receptor enhancer with antidepressant effects. TAK-137 has the ability to improve cognition and could be used to study schizophrenia.
-
UK-240455
UK-240455 is a potent and selective N-methyl-D-aspartic acid (NMDA) glycine receptor antagonist with neuroprotective effects and improvements in motor function in Parkinson's disease models, making it a potential candidate for Parkinson's disease treatment.
